BACKGROUND: Plasmacytoid urothelial carcinoma is a rare bladder cancer variant with scarce data on outcomes and prognostic factors. OBJECTIVE: We report our institutional experience with this histology to determine response to neoadjuvant chemotherapy, definitive surgery and survival. METHODS: We conducted a retrospective chart review of consecutive patients with plasmacytoid, as well as conventional urothelial carcinoma (for comparison) seen in our institution (2007 - 2018). Baseline characteristics, clinicopathologic and treatment data were captured. T-test, chi-squared and log-rank test was used for group comparison. Kaplan Meier method was used for estimation of overall survival and Cox regression for identification of prognostic factors. RESULTS: 64 patients with plasmacytoid and 418 with conventional urothelial histology were identified; 53% of those with plasmacytoid presented with cT3/4 stage and 67% underwent extirpative surgery. Patients with plasmacytoid histology had higher rates of pT3/4 (65% vs. 28%), nodal disease (37% vs. 16%) and positive surgical margins (23% vs. 5%) compared to urothelial group (p < 0.01), as well as higher incidence of post-operative recurrence (47% vs. 29%, p = 0.05) and lower ypT0N0 rates after neoadjuvant chemotherapy (10% vs. 33%, p = 0.03). Plasmacytoid histology was associated with lower median overall survival compared to conventional urothelial (24 vs. 154 months, p < 0.01). CONCLUSIONS: Plasmacytoid urothelial carcinoma frequently presented with advanced stage at diagnosis and extirpative surgery, poor pathologic response to neoadjuvant chemotherapy, and inferior outcomes, when compared to conventional urothelial. Prospective trials evaluating upfront cystectomy versus preoperative chemotherapy and/or novel treatments should be considered.
BACKGROUND: Plasmacytoid urothelial carcinoma is a rare bladder cancer variant with scarce data on outcomes and prognostic factors. OBJECTIVE: We report our institutional experience with this histology to determine response to neoadjuvant chemotherapy, definitive surgery and survival. METHODS: We conducted a retrospective chart review of consecutive patients with plasmacytoid, as well as conventional urothelial carcinoma (for comparison) seen in our institution (2007 - 2018). Baseline characteristics, clinicopathologic and treatment data were captured. T-test, chi-squared and log-rank test was used for group comparison. Kaplan Meier method was used for estimation of overall survival and Cox regression for identification of prognostic factors. RESULTS: 64 patients with plasmacytoid and 418 with conventional urothelial histology were identified; 53% of those with plasmacytoid presented with cT3/4 stage and 67% underwent extirpative surgery. Patients with plasmacytoid histology had higher rates of pT3/4 (65% vs. 28%), nodal disease (37% vs. 16%) and positive surgical margins (23% vs. 5%) compared to urothelial group (p < 0.01), as well as higher incidence of post-operative recurrence (47% vs. 29%, p = 0.05) and lower ypT0N0 rates after neoadjuvant chemotherapy (10% vs. 33%, p = 0.03). Plasmacytoid histology was associated with lower median overall survival compared to conventional urothelial (24 vs. 154 months, p < 0.01). CONCLUSIONS: Plasmacytoid urothelial carcinoma frequently presented with advanced stage at diagnosis and extirpative surgery, poor pathologic response to neoadjuvant chemotherapy, and inferior outcomes, when compared to conventional urothelial. Prospective trials evaluating upfront cystectomy versus preoperative chemotherapy and/or novel treatments should be considered.
Authors: Nicholas J Hellenthal; Abid Hussain; Paul E Andrews; Paul Carpentier; Erik Castle; Prokar Dasgupta; Jihad Kaouk; Shamim Khan; Adam Kibel; Hyung Kim; Murugesan Manoharan; Mani Menon; Alex Mottrie; David Ornstein; Joan Palou; James Peabody; Raj Pruthi; Lee Richstone; Francis Schanne; Hans Stricker; Raju Thomas; Peter Wiklund; Greg Wilding; Khurshid A Guru Journal: J Urol Date: 2010-05-15 Impact factor: 7.450
Authors: Bastian Keck; Robert Stoehr; Sven Wach; Anja Rogler; Ferdinand Hofstaedter; Jan Lehmann; Rodolfo Montironi; Mathilde Sibonye; Hans M Fritsche; Antonio Lopez-Beltran; Jonathan I Epstein; Bernd Wullich; Arndt Hartmann Journal: Int J Cancer Date: 2010-12-01 Impact factor: 7.396
Authors: Hikmat A Al-Ahmadie; Gopa Iyer; Byron H Lee; Sasinya N Scott; Rohit Mehra; Aditya Bagrodia; Emmet J Jordan; Sizhi Paul Gao; Ricardo Ramirez; Eugene K Cha; Neil B Desai; Emily C Zabor; Irina Ostrovnaya; Anuradha Gopalan; Ying-Bei Chen; Samson W Fine; Satish K Tickoo; Anupama Gandhi; Joseph Hreiki; Agnès Viale; Maria E Arcila; Guido Dalbagni; Jonathan E Rosenberg; Bernard H Bochner; Dean F Bajorin; Michael F Berger; Victor E Reuter; Barry S Taylor; David B Solit Journal: Nat Genet Date: 2016-02-22 Impact factor: 38.330
Authors: Qiang Li; Melissa Assel; Nicole E Benfante; Eugene J Pietzak; Harry W Herr; Machele Donat; Eugene K Cha; Timothy F Donahue; Bernard H Bochner; Guido Dalbagni Journal: Eur Urol Focus Date: 2017-06-27
Authors: Roberto Rafael Ricardo-Gonzalez; Michael Nguyen; Neriman Gokden; Ankur R Sangoi; Joseph C Presti; Jesse K McKenney Journal: J Urol Date: 2012-01-15 Impact factor: 7.450
Authors: Shahrokh F Shariat; Pierre I Karakiewicz; Ganesh S Palapattu; Yair Lotan; Craig G Rogers; Gilad E Amiel; Amnon Vazina; Amit Gupta; Patrick J Bastian; Arthur I Sagalowsky; Mark P Schoenberg; Seth P Lerner Journal: J Urol Date: 2006-12 Impact factor: 7.450
Authors: Carmen M Perrino; John Eble; Chia-Sui Kao; Rumeal D Whaley; Liang Cheng; Mohammad Idrees; Neda Hashemi-Sadraei; M Francesa Monn; Hristos Z Kaimakliotis; Elhaam Bandali; David Grignon Journal: Hum Pathol Date: 2019-05-03 Impact factor: 3.466
Authors: Farshid Dayyani; Bogdan A Czerniak; Kanishka Sircar; Mark F Munsell; Randall E Millikan; Colin P Dinney; Arlene O Siefker-Radtke Journal: J Urol Date: 2012-11-15 Impact factor: 7.450
Authors: Nicholas E Power; Wassim Kassouf; David Bell; Armen G Aprikian; Yves Fradet; Louis Lacombe; Joseph Chin; Jonathan Izawa; Eric Estey; Adrian Fairey; Ilias Cagiannos; Jean-Baptiste Lattouf; Darrel Drachenberg; Ricardo A Rendon Journal: Can Urol Assoc J Date: 2012-12 Impact factor: 1.862
Authors: Gabriele Sorce; Rocco Simone Flammia; Benedikt Hoeh; Francesco Chierigo; Benedikt Horlemann; Christoph Würnschimmel; Zhe Tian; Markus Graefen; Carlo Terrone; Michele Gallucci; Felix K H Chun; Fred Saad; Shahrokh F Shariat; Francesco Montorsi; Alberto Briganti; Pierre I Karakiewicz Journal: World J Urol Date: 2022-01-27 Impact factor: 3.661